financetom
Business
financetom
/
Business
/
Monday.com Q1 Non-GAAP Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Monday.com Q1 Non-GAAP Earnings, Revenue Rise
May 26, 2025 5:44 AM

07:31 AM EDT, 05/12/2025 (MT Newswires) -- Monday.com ( MNDY ) reported Q1 non-GAAP earnings Monday of $1.10 per diluted share, up from $0.61 a year earlier.

Analysts polled by FactSet expected $0.70.

Revenue for the quarter ended March 31 was $282.3 million, up from $216.9 million a year earlier.

Analysts surveyed by FactSet expected $275.8 million.

The company said it expects Q2 revenue of $292 million to $294 million. Analysts surveyed by FactSet project $294 million.

For 2025, Monday.com ( MNDY ) now expects revenue of $1.22 billion to $1.23 billion, compared with its prior outlook of $1.21 billion to $1.22 billion. Analysts polled by FactSet expect $1.21 billion.

The company's shares were up 5.6% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Grifols in Talks With Banks to Extend Credit Facility, Refinance Bonds
Market Chatter: Grifols in Talks With Banks to Extend Credit Facility, Refinance Bonds
Nov 29, 2024
12:17 PM EST, 11/29/2024 (MT Newswires) -- Grifols ( GRFS ) is in discussions with banks to extend a $1 billion revolving credit facility and refinance 370 million euros ($390.3 million) in bonds due 2025, Bloomberg News reported Thursday, citing an interview with Chief Executive Officer Nacho Abia. Several banks have already confirmed interest in refinancing, even expanding the facility,...
EU regulators scrap merger power aimed at killer acquisitions after court veto
EU regulators scrap merger power aimed at killer acquisitions after court veto
Nov 29, 2024
BRUSSELS, Nov 29 (Reuters) - EU antitrust regulators on Friday ditched a merger tool aimed at killer acquisitions two months after Europe's top court vetoed this expanded merger power which had been widely criticised by companies as regulatory over-reach. The Luxembourg-based Court of Justice in September sided with Illumina ( ILMN ) in its fight against the European Commission's decision...
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says
Nov 29, 2024
12:15 PM EST, 11/29/2024 (MT Newswires) -- Applied Therapeutics' ( APLT ) lead drug candidate, govorestat, likely faces significant uncertainty in potentially treating galactosemia after the US Food and Drug Administration rejected the biopharmaceutical company's drug application, RBC Capital Markets said Friday. Late Wednesday, the clinical-stage company said the FDA is unable to approve govorestat's new drug application for the...
EU regulators scrap merger power aimed at killer acquisitions after court veto
EU regulators scrap merger power aimed at killer acquisitions after court veto
Nov 29, 2024
BRUSSELS (Reuters) - EU antitrust regulators on Friday ditched a merger tool aimed at killer acquisitions two months after Europe's top court vetoed this expanded merger power which had been widely criticised by companies as regulatory over-reach. The Luxembourg-based Court of Justice in September sided with Illumina ( ILMN ) in its fight against the European Commission's decision to wield...
Copyright 2023-2026 - www.financetom.com All Rights Reserved